Objectives-Previous studies demonstrated increased levels of cysteine proteases cathepsins in serum and adipose tissues from obese patients. We now provide evidence from a mouse model of obesity to suggest a direct participation of cathepsin K (CatK) in mouse body weight gain and glucose metabolism. Methods and Results-Using real-time polymerase chain reaction, we detected 12-fold increase in CatK transcripts after adipogenesis of human preadipocytes. Using an immunohistology analysis, we consistently observed high levels of CatK expression in adipose tissues from obese humans and mice. Selective inhibition of CatK activity blocked the lipid accumulation in human and mouse preadipocytes. In mice, CatK deficiency reduced significantly diet-induced body weight gain and serum glucose and insulin levels. Similar results were obtained in diet-induced and genetically created (ob/ob) obese mice after animals were treated with a CatK-selective inhibitor. Mechanistic study demonstrated a role for CatK in degrading fibronectin, a matrix protein that controls adipogenesis. Deficiency or inhibition of CatK leads to fibronectin accumulation in muscle and adipose tissues.
C ysteine protease cathepsins play important roles in cancer, autoimmune diseases, infectious diseases, and cardiovascular diseases. Recent observations indicate that expression of cathepsin S (CatS) is associated with adipogenesis and obesity in humans. Increased expression of CatS, both at RNA and protein levels, has been reported in subcutaneous adipose tissues of obese patients, 1 where CatS mRNA levels are significantly associated with body mass index. In humans, surgery-induced weight loss is associated with significant reduction of CatS levels in serum and white adipose tissues. 2 In cultured human preadipocytes, inhibition of CatS reduced cell adipogenesis. 3 It has been suggested that CatS participates in adipogenesis by degrading fibronectin, an important extracellular matrix protein that regulates preadipocyte differentiation 4 via downregulation of lipogenic gene expression and interference with cytoskeletal and morphological changes necessary for new gene expression. 5 Similar to CatS, increased CatK expression was also detected in differentiated preadipocyte 3T3-L1 and in adipose tissues from db/db obese mice, especially in lysosome-enriched fractions. 6, 7 However, it remains unknown whether increased levels of cathepsins in human/murine adipose tissue or serum merely serve as a hallmark of inflammation, and more importantly, whether cathepsins offer a potential drug target to control human obesity. 1, 2, 6, 7 In this study, we demonstrate that CatK is highly expressed in adipose tissues from obese humans and mice. Deficiency or selective inhibition of CatK activity reduces preadipocyte differentiation and impairs mouse body weight gain in dietinduced and genetically created obese mice.
Methods

Preadipocyte Culture and Differentiation
Human subcutaneous preadipocytes (Cambrex Corporation) and murine 3T3-L1 were differentiated with or without a nonselective cathepsin inhibitor E64d (20 mol/L, Sigma), a CatK-selective inhibitor-II (0.5ϳ1 mol/L, Calbiochem), or a CatS-selective inhibitor N-morpholinurea-leucine-homophenylalanine-vinylsulfonephenyl (LHVS) 8 as we described previously. 9 Differentiated human and mouse adipocytes were fixed and stained with oil-red O. To quantify adipogenesis, we extracted intracellular oil-red O with 100% isopropanol and quantified OD 510 nm . Data were presented as percentage of OD 510 nm reading relative to cells without protease inhibitors.
Real-Time PCR
Real-time PCR and data analysis were performed as described elsewhere. 10 Five human housekeeping genes, peptidylprolyl isomerase A (PPIA), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), eukaryotic elongation factor 1A (EEF1A), ribosomal protein L13a (RPL13A), and ubiquitin, were used as experimental controls.
Mice
CatK knockout mice (CatK Ϫ/Ϫ ) (C57BL/6/129S background) 11 and their littermates (CatK ϩ/ϩ , CatK ϩ/Ϫ ) began a high-fat diet (HFD, Research Diet) at 6 weeks of age for 16 weeks. Body weight was monitored biweekly. To examine the effect of CatK inhibitor in mouse body weight gain, we started feeding female wild-type mice (C57BL/6, 6 weeks old) a HFD while also giving mice a CatKselective inhibitor K4b (1 mg/kg/d) or DMSO for 14 weeks. Mouse body weight was monitored biweekly. To examine the ability of K4b to control body weight gain in ob/ob mice, we treated 4-week-old female ob/ob mice (C57BL/6, Jackson Laboratory, Bar Harbor, Maine) with K4b (1 mg/kg/d) for 8 weeks. Because of fast body weight gain of ob/ob mice, we monitored their body weight weekly. Energy expenditure, serum insulin level, and glucose tolerance were determined as we previously reported. 9
Immunohistology
Paraffin sections of human white adipose tissue and normal muscle (nϭ9 per group with unknown gender and age) were obtained from the Department of Pathology, Brigham and Women's Hospital under a preapproved human subject research protocol. Mouse visceral fat and muscle tissues were fixed in 3% paraformaldehyde and paraffin sections were prepared for immunostaining with antibodies against human fibronectin (1:10,000, Dako), mouse fibronectin (1:10,000, NeoMarkers), mouse CatK (1:75, Calbiochem), and mouse Mac-2 (1:1200, Cedarlane Laboratories, Ontario, Canada).
Western Blot
Equal amount of proteins (40 g/lane) from fat, muscle, or 3T3-L1 cells were separated on 8% SDS-PAGE for immunoblot analysis with antimouse fibronectin (1:200, NeoMarkers), Glut4 (1:100, R&D Systems), insulin receptor (IR) ␤-subunit (1:200, Calbiochem), CatK (1:1000, Santa Cruz), and tubulin (1:1000, Santa Cruz) monoclonal antibodies, and anti-GAPDH (1:1000, Abcam) and CatK (1:1000) polyclonal antibodies.
In Vitro Fibronectin Digestion With CatK
Human plasma fibronectin (10 g/reaction, Chemicon) was incubated with different amounts of recombinant human CatK (Calbiochem) in a pH5.5 buffer. 12 After 45 minutes of incubation at 37°C, samples were separated on a 8% SDS-PAGE.
Cysteine Protease Active Site Labeling and Immunoprecipitation
Active cathepsins in mouse splenocytes, peritoneal macrophages, fat and muscle tissues were detected by incubating protein lysate (50 g/sample) with [ 125 I]-JPM as we previously described. 12 To examine the inhibitory specificities of cathepsin inhibitors in mouse adipocytes, differentiated 3T3-L1 cells were incubated with E64 days (20 mol/L) or CatK-selective inhibitor-II (0.5 to 1 mol/L) for 6 hours followed by labeling the cell lysate (200 g/sample) with [ 125 I]-JPM at 37°C for 1 hour. Labeled cell lysate was neutralized with 1 mol/L Tris.HCl, pH10.0, boiled for 5 to 10 minutes, and then incubated with mouse CatK monoclonal antibody (Santa Cruz)coated protein A agarose beads at 4°C overnight. Affinity bound CatK proteins were boiled and separated on a 12% SDS-PAGE.
Statistics
Because of the relative small sample sizes and data distribution abnormality, we selected the nonparametric Mann-Whitney test to examine the statistical significances throughout this study. PϽ0.05 were considered significant.
Results
Expression of Cathepsins and Cathepsin Inhibitors in Human Adipocytes
Increased expression of CatS and CatK have been detected in human adipocytes, 3,6 but a broad view of cathepsin expression profile is still unavailable. Following the process of human primary adipocyte differentiation, we measured the mRNA levels of a list of selected cathepsins and their endogenous inhibitors cystatins with real-time PCR. As shown in supplemental Table I (available online at http:// atvb.ahajournals.org), among all tested cathepsins, CatS and CatK demonstrated the highest induction after preadipocyte differentiation (ϳ12-fold). In human adipocytes, CatB, CatK, and CatL transcripts were 42-to 100-fold greater than those of CatS. In contrast, among all tested cystatins, cystatin C is the most abundant cathepsin inhibitor, Ͼ30to 2000-fold more transcripts than other cystatins. Importantly, although all tested cathepsins are increased after preadipocyte differentiation, cystatin C expression remains unchanged.
CatK Inhibition Reduces Human Preadipocyte Adipogenesis
Increased expression of CatK in human adipocytes suggests its high expression in human adipose tissues. Using human CatK antibody-mediated immunohistology analysis, we detected CatK expression in human adipose tissues (supplemental Figure IB ), but negligibly in human skeletal muscles (supplemental Figure IA) . Although prior experiments from Xiao et al 6 demonstrated that the nonselective cathepsin inhibitor E64 reduces human preadipocyte differentiation, it is unknown whether their observations were attributable to the inhibition of CatK or other cathepsins. To test this possibility, we differentiated human preadipocytes in the presence of Boc-Phe-Leu-NHNH-CO-NHNH-Leu-Z (Calbiochem), a CatK inhibitor that is 50-fold more sensitive to CatK than CatL and 2 to 4 orders of magnitude more selective to CatK than to CatB or papain. 13 Oil-red O staining showed adipogenesis or lipid accumulation after the cells were induced for differentiation. When human preadipocytes were incubated with E64d (20 mol/L), we observed strong inhibition of adipogenesis. When we used 0.5 to 1 mol/L of CatK-selective inhibitor, concentrations that inhibited CatK (supplemental Figure IIB 
CatK Expression in Mouse Adipose Tissues
Visceral fat from HFD-induced obese mice contains CatK. By coimmunostaining mouse adipose tissue section with CatK polyclonal antibody (red) and Mac-2 (macrophages, green) monoclonal antibody, we detected clusters of CatKpositive macrophages (orange) in the adipose tissues ( Figure  1A) , indicating an infiltration of CatK-positive macrophages to the adipose tissues. When we labeled the fat and muscle tissue extracts with a cysteine protease active site probe [ 125 I]-JPM, which detects only active cathepsins, we revealed much stronger total cathepsin activities in the fat than the muscle. Importantly, fat from obese mice contained even more cathepsin activities than fat from lean mice ( Figure 1B) . These cathepsins may come in part from infiltrated macrophages. Immunoblot analysis using an antimouse CatK monoclonal antibody we demonstrated higher amount of the 28-kDa active form of CatK proteins in fat tissues from obese mice than those of lean mice. In contrast, we detected negligible CatK signals in muscles from either obese or lean mice under this experimental condition ( Figure 1C ).
CatK Inhibition Reduces 3T3-L1 Cell Adipogenesis
Increased CatK expression in mouse adipose tissues ( Figure  1A and 1C) suggests its participation in mouse preadipocyte differentiation. To examine this hypothesis, we induced 3T3-L1 cells in the presence of nonselective cathepsin inhibitor E64d and CatK-selective inhibitor. Insulin-induced 3T3-L1 cell differentiation is clearly blocked by E64d (20 mol/L) and CatK-selective inhibitor (0. 
CatK Deficiency Reduces Body Weight Gain in Mice
Increased CatK expression in human and mouse adipose tissue could be one of the hallmarks of obesity. To examine the direct participation of CatK in obesity, we fed CatKdeficient (CatK Ϫ/Ϫ ) and heterozygous (CatK ϩ/Ϫ ) mice a HFD for 16 weeks to induce obesity. Compared with wild-type littermate control (CatK ϩ/ϩ ) mice, overall body weight was reduced in male CatK Ϫ/Ϫ and CatK ϩ/Ϫ mice (Figure 2A ), but most data points did not reach statistical significance. However, body weight gain in female CatK Ϫ/Ϫ mice was significantly reduced compared with that of female CatK ϩ/ϩ mice at later time points ( Figure 2B ). To test whether reduced body weight gain in female CatK Ϫ/Ϫ mice was attributable to possible alterations of food/water consumption or metabolic rate, we performed energy expenditure analysis in mice that consumed a HFD by monitoring mouse food consumption (gram/24 hours), water uptake (ml/24 hours), O 2 consumption (ml/min), CO 2 production (ml/min), and metabolic rate (cal/ min), and found no significant differences in these parameters between CatK ϩ/ϩ and CatK Ϫ/Ϫ mice (supplemental Table II ). Importantly, CatK contributes to body weight gain in a gene dose-dependent manner. CatK ϩ/Ϫ mice gained more weight than CatK Ϫ/Ϫ mice but less than the CatK ϩ/ϩ mice ( Figure  2B ). Consistent with reduced body weight gain, both male and female CatK Ϫ/Ϫ mice demonstrated significant reduction of total visceral and subcutaneous fat weight compared with those of the CatK ϩ/ϩ mice, and such reductions were more prominent in females ( Figure 2C ). Interestingly, adipocytes in CatK Ϫ/Ϫ mice visceral fat are bigger than those from CatK ϩ/ϩ mice ( Figure 2D ), suggesting reduced adipocyte contents in CatK Ϫ/Ϫ mouse adipose tissues. Therefore, lean fat does not necessarily contain small adipocytes. The same is true in collagen VI-null mice, which also gained less body weight but had larger adipocytes than the wild-type controls, although mechanisms behind these phenotypes remain unknown. 14 Prior in vitro studies suggest that CatS promotes adipogenesis by degrading fibronectin, 3 an extracellular matrix protein that regulates preadipocyte differentiation. 5 When 3T3-L1 cells were cultured on fibronectin-precoated plates, adipogenesis was impaired. 4 Therefore, we examined whether reduced body weight gain in CatK Ϫ/Ϫ mice correlated with higher tissue fibronectin levels. Using immunoblot analysis, we did detect fibronectin accumulation in fat ( Figure 2E ) and muscle ( Figure 2F ) from CatK Ϫ/Ϫ mice. Female mice had lower body weight (Figure  2A and 2B) and less adipose tissues ( Figure 2C ) and higher fibronectin proteins in the fat ( Figure 2E ) and muscle ( Figure 2F ) compared with those in male mice (Figure 2A , 2B, 2C, 2E, and 2F). Increased tissue fibronectin levels in CatK Ϫ/Ϫ mice or female mice were not attributable to altered gene transcription. RT-PCR analysis did not reveal significant differences of fibronectin transcripts among different genotypes or genders ( Figure 2G ). Similar results were obtained from immunohistology analysis. Strong immunogenic fibronectin signals were detected in fat and muscle from CatK Ϫ/Ϫ mice, but were almost negligible in tissues from the CatK ϩ/ϩ mice ( Figure 2H ). These observations suggest a role of CatK in adipogenesis in part by reducing tissue fibronectin protein levels. To examine this hypothesis in vitro, we digested human plasma fibronectin with recombinant human CatK. Fibronectin digestion with 1 to 250 nmol/L of CatK yielded 90 to 110 kDa degradation fragments ( Figure 2I ).
CatK Deficiency Reduces Mouse Serum Insulin and Glucose Levels
Visceral obesity is often associated with increased serum glucose and insulin levels. 15 Therefore, it is possible that reduced body weight gain in female CatK Ϫ/Ϫ mice associates with a reduction of serum insulin levels. To examine this possibility, we detected a significant reduction of serum insulin in CatK Ϫ/Ϫ mice (both males and females) with an insulin ELISA kit. Although lower serum insulin levels were also observed in CatK ϩ/Ϫ mice, this reduction did not reach statistical significance ( Figure 3A) . It is possible that reduced serum insulin in CatK Ϫ/Ϫ mice could result from enhanced insulin metabolism, mediated by IR. To test this hypothesis, we performed immunoblot analysis in visceral fat and skeletal muscle from female mice. Although we did not detect differences in IR protein levels in fat from different mice ( Figure 3B ), increased levels of IR (95-kDa ␤-subunit) were detected in muscles from CatK Ϫ/Ϫ and CatK ϩ/Ϫ mice ( Figure  3C ), suggesting that IR turnover in the endosomal compartment requires CatK. 16 By measuring fasted mouse serum glucose levels, we detected significant reduction in female CatK Ϫ/Ϫ (PϽ0.02) and CatK ϩ/Ϫ (PϽ0.04) mice but not in males ( Figure 3D ), indicating improved insulin sensitivity in CatK Ϫ/Ϫ mice. Muscle has long been considered the major site of insulininduced glucose uptake in vivo, 17 mediated by a family of glucose transporter proteins, which are expressed in specific tissues. Among these proteins, Glut4 is the major glucose transporter isoform in tissues that exhibit insulinstimulated glucose uptake, such as adipose tissue and skeletal muscle. 18 Consistently, both fat and muscle tissues from CatK Ϫ/Ϫ and CatK ϩ/Ϫ mice also contain higher amounts of Glut4 than tissues from CatK ϩ/ϩ mice ( Figure  3E and 3F ).
CatK Inhibition Reduces Body Weight Gain in Mice
We tested whether we could reduce mouse body weight gain by selectively inhibiting CatK activity. A recently discovered CatK-selective inhibitor N␣-phenoxybenzyloxycarbonyl-Lleucine(2-phenylaminoethyl)amide (K4b) was prepared according to an established method. 19 K4b inhibits preferentially CatK with IC 50 Ͻ0.006 mol/L, whereas it inhibits cathepsins S and L with IC 50 Ͼ10 mol/L. 19 Because significantly reduced body weight gain was observed mainly in female CatK Ϫ/Ϫ mice ( Figure 2B) , we injected female wild-type C57BL/6 mice intraperitoneally with K4b (1 mg/kg/d) and detected reduction of HFD-induced body weight gain, although some time points did not reach statistical significance ( Figure 4A ). To examine whether K4b inhibited other major tissue cathepsins under this concentration, we performed cathepsin active site labeling using splenocyte, one of the best tissue cell types expressing spectrum of cathepsins, harvested 6, 12, and 24 hours after K4b injection, which did not reveal obvious inhibition of CatB, CatS, or CatL (not shown). CatK inhibition with K4b also increased the fibronectin levels in skeletal muscle and visceral fat ( Figure  4B) . In contrast, fat or muscle from obese wild-type C57BL/6 mice that were injected with vehicle (DMSO) contained negligible fibronectin (not shown).
Genetically altered ob/ob mice on a chow diet gain body weight consistently. Mice received K4b (1 mg/kg/d) at 4 weeks of age, when wild-type mice and ob/ob mice did not show significant body weight differences. Female ob/ob mice that received K4b demonstrated significant reduction of body weight gain at all time points tested compared with those that received only vehicle ( Figure 4C ). In ob/ob mice, inhibition of CatK with K4b also led to accumulations of both muscle and fat fibronectin ( Figure 4D ). However, all tested energy expenditure parameters, including food/water intake, O 2 consumption, CO 2 production, and metabolic rate were not affected in C57BL/6 or ob/ob mice by this compound (not shown).
Discussion
Both CatS and CatK are expressed in adipose tissues from humans and mice. 1, 2, 7 However, increased expression of these proteases can be the result of inflammatory infiltrates, including macrophages and lymphocytes. It is now well accepted that macrophages, rich in cathepsin expression, are recruited to the adipose tissues 20 where they further polarize to adipose tissue-specific macrophages. 21 In diet-induced obese mice, consumption of a HFD also stimulates adipose tissue chemokine expression for the recruitment of macrophages, lymphocytes, and other inflammatory cells. Recent studies suggest that CatS promotes human preadipocyte differentiation. 3 Inhibition of CatS activity delayed adipogenesis. These data are consistent with our finding that CatS and CatK had the greatest induction among all tested cathepsins after human preadipocyte differentiation (supplemental Table I ). Although we cannot exclude the possibility that CatS controls human adipogenesis, we did not see reduced body weight gain from a HFD-fed CatS/low-density lipoprotein receptor (LDLr) 12 or CatS/apolipoprotein E (ApoE) (Shi, unpublished data) double mutant mice compared with their wild-type controls. We do not know whether these phenotypes were attributable to the deficiency of LDLr or ApoE or because CatS expression levels were too low relative to other cathepsins (42-to 100-fold less than CatB, CatK, and CatL; supplemental Table  I ), or perhaps human CatS acts differently from mouse CatS. These theories remain to be examined.
In this study, we used an in vitro human and murine preadipocyte culture system, genetically altered mice, and pharmacologically treated obese mice to test a hypothesis that CatK participates directly in obesity. Although the exact mechanisms by which CatK participates in adipogenesis or obesity require further investigation, our data suggest that CatK affects at least two molecules that are essential to adipogenesis: fibronectin and IR ␤-subunit. Participation of fibronectin in adipogenesis has been proposed since the early 1980s. 5 Although mice lacking fibronectin are lethal, 22 which makes it difficult to test a direct role of fibronectin in obesity, human and murine preadipocytes fail to differentiate on fibronectin precoated culture dishes. 4 Significant inhibition of adipogenesis was also observed when mouse 3T3-L1 cells were cultured in 5 to 15 g/mL of fibronectin (data not shown). In this study, we demonstrated in vitro that CatK degraded 220-kDa fibronectin into 90-to 110-kDa fragments. Similar size fragments were also detected from fat and muscle tissues from CatK ϩ/ϩ mice (Figure 2E and 2F ), suggesting an in situ CatK activity in fibronectin degradation. However, this hypothesis is challenged by the observations of 90-to 110-kDa fibronectin fragment production in tissues from CatK Ϫ/Ϫ mice (Figure 2E and 2F) . Therefore, proteases other than CatK are also involved in native fibronectin proteolysis. Nevertheless, we detected accumulation of fibronectin in fat and muscle from both CatK Ϫ/Ϫ mice and CatK inhibitor-treated mice (Figures 2E, 2F, 2H, 4B, and 4D) , which may account at least in part for the reduced body weight gain in these mice.
Internalization of insulin-IR complex contributes to insulin clearance 23 However, the exact intracellular enzyme(s) responsible for this processing pathway remains unidentified. Prior studies suggested a role of thio-proteases in IR catabolism. 24 Despite the observation that the rate of insulin-IR internalization and degradation is reduced in cells from obese patients, the pathological implication of altered IR processing remains unknown. It is anticipated that alteration of IR processing influences insulin action and glucose metabolism. Indeed, obese Zucker fatty rats treated with E64 demonstrated reduced proteolysis of cell membrane IR ␤-subunits 25 and improved the insulin resistance. 24 Our observations demonstrated that CatK was one of these thio-proteases responsible for IR ␤-chain processing, and absence of CatK resulted in accumulation of IR ␤-chain ( Figure 3C ). We also showed that CatK-deficiency reduced insulin and glucose circulating levels ( Figure 3A and 3D) . These changes could be secondary to reduced weight gain in CatK Ϫ/Ϫ mice. Alternatively, CatKdeficiency could improve insulin action per se, by undefined cellular and molecular mechanisms. Among the potential candidates, increased Glut4 expression in muscles and fat of CatK Ϫ/Ϫ mice ( Figure 3E and F) could contribute in part to improve insulin effect on glucose utilization. 18 Although body weight gain showed no significant differences between male CatK Ϫ/Ϫ and CatK ϩ/ϩ mice (Figure 2A and 2B), serum insulin levels did ( Figure 3A) . In contrast, both body weight gain and serum insulin levels are reduced in female CatK Ϫ/Ϫ mice, compared with female CatK ϩ/ϩ mice. Therefore, at least two questions remain. First, why are female mice more sensitive to CatK than male mice in body weight gain? Cathepsins play a role in hormone activation or degradation. For examples, cathepsins produce active forms of thyroid hormones, 26 which regulate body weight gain. 27 It is possible that obesity-associated hormone activation by CatK is differentially regulated in different genders. Second, why did male CatK Ϫ/Ϫ and CatK ϩ/ϩ mice show differences in serum insulin levels (Pϭ0.02; Figure 3A ) but less so in body weight gain (Figure 2A) ? These observations suggest different mechanisms of body weight gain and insulin secretion or clearance, although how CatK involves in these regulations remains unknown.
In conclusion, our data suggest an important participation of cysteine protease CatK in obesity by degrading matrix protein fibronectin. Deficiency and pharmacological inhibition of CatK reduces mouse body weight gain, indicating a potential means of controlling human obesity by targeting CatK activity. 
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